GlassScriptPhysician profile
Cindy Yusing Wang
NPI 1982966214
$5,042.39
in general payments reported to CMS, 2019-2025
25 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,736 · 2020: $288 · 2021: $662 · 2022: $141 · 2023: $633 · 2024: $555 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,992.17 | 2019-2025 | Amplatzer Amulet |
| Novartis Pharmaceuticals Corporation | $432.08 | 2019-2025 | |
| Pfizer INC. | $323.08 | 2022-2025 | |
| Medtronic, INC. | $253.91 | 2025 | Aurora Ev-Icd Mri Surescan, Omniasecure Mri Surescan |
| Amgen INC. | $253.49 | 2020-2025 | Repatha, Repatha |
| Novo Nordisk INC | $244.12 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $171.04 | 2023-2025 | Amvuttra, Onpattro |
| Esperion Therapeutics, INC. | $169.20 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $150.53 | 2023-2025 | Jardiance |
| Biosense Webster, INC. | $146.86 | 2025 | Carto 3 |
| Gilead Sciences, INC. | $121.82 | 2023 | Veklury |
| Astrazeneca Pharmaceuticals LP | $112.18 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $106.52 | 2021-2024 | Xarelto |
| Edwards Lifesciences Corporation | $91.53 | 2024-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Boston Scientific Corporation | $71.12 | 2024-2025 | Watchman Flx |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $70.18 | 2023-2024 | Verquvo |
| Astellas Pharma US INC | $68.27 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $63.45 | 2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $62.38 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $42.36 | 2025 | Eliquis |
| Amarin Pharma, INC. | $23.28 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $23.09 | 2021 | |
| Heartflow, INC. | $17.14 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $16.38 | 2024 | Arcalyst |
| Kowa Pharmaceuticals America, INC. | $16.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.